CD40LG and COVID-19: Considering the per capita GDP of Iran and the threshold defined by WHO that if the ICER is less than three times the GDP per capita, the intervention is cost-effective, so in this study, in the scenarios with 5, 10, and 50% prevalence of COVID-19, respectively PCR, PCR, and IgG&IgM strategies are cost-effective.